Dupixent® (dupilumab) approved by european commission as first and only targeted medicine for children as young as six months old with severe atopic dermatitis

Approximately seven times as many patients aged 6 months to 5 years with severe atopic dermatitis treated with dupixent experienced clear or almost clear skin and reduced overall disease severity compared to placebo

REGN Ratings Summary

REGN Quant Ranking